Karina Thorn

Title: Inventor Spotlight: Karina Thorn from Farum, Denmark

Introduction

Karina Thorn is an accomplished inventor based in Farum, Denmark, known for her significant contributions to the field of biomedicine. Her innovative work has led to the development of four patents, focusing on treatments for coagulopathy, particularly in conditions such as haemophilia A.

Latest Patents

Karina's latest patents include advancements in the production of procoagulant antibodies. These improved antibodies possess the ability to bind to coagulation Factor IX (FIX) or its activated form, Factor IXa (FIXa), along with optional binding to Factor X (FX) and its activated form, Factor Xa (FXa). This innovation promotes FX activation by FIXa, thereby aiding in the treatment of individuals with coagulation disorders. Another notable patent involves unique FX binding molecules, including antibodies and their fragments, which demonstrate potential in improving treatments for haemophilia.

Career Highlights

Throughout her career, Karina has worked with esteemed organizations such as Novo Nordisk A/S and Biovertiv Therapeutics Inc. These experiences have provided her with a platform to further her research and enhance her inventions in the field of coagulopathy treatments.

Collaborations

Karina has collaborated with prominent colleagues like Mikkel Nors Harndahl and Bjarne Gram Hansen. Together, they have combined their expertise to push the boundaries of biomedical research, leading to groundbreaking advancements in treatment methods for coagulation disorders.

Conclusion

Karina Thorn exemplifies the spirit of innovation in the biomedical industry. Her dedication to developing new therapies for coagulopathy, supported by her robust patent portfolio and collaborative efforts, showcases her vital role in improving patient care and treatment outcomes.